Qiagen N.V. (QGEN): Price and Financial Metrics

Qiagen N.V. (QGEN): $54.25

0.26 (+0.48%)

POWR Rating

Component Grades













Add QGEN to Watchlist
Sign Up

Industry: Biotech


of 508

in industry


  • QGEN scores best on the Stability dimension, with a Stability rank ahead of 83.94% of US stocks.
  • The strongest trend for QGEN is in Growth, which has been heading down over the past 52 weeks.
  • QGEN ranks lowest in Momentum; there it ranks in the 50th percentile.

QGEN Stock Summary

  • QGEN has a market capitalization of $12,239,424,080 -- more than approximately 82.81% of US stocks.
  • Over the past twelve months, QGEN has reported earnings growth of 101.99%, putting it ahead of 80.55% of US stocks in our set.
  • In terms of volatility of its share price, QGEN is more volatile than just 11.19% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Qiagen Nv, a group of peers worth examining would be LFUS, BDC, FOXF, HPE, and ANGO.
  • Visit QGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.qiagen.com.

QGEN Valuation Summary

  • In comparison to the median Healthcare stock, QGEN's EV/EBIT ratio is 25.94% lower, now standing at 21.7.
  • QGEN's price/earnings ratio has moved down 50.8 over the prior 239 months.
  • Over the past 239 months, QGEN's price/sales ratio has gone down 4.3.

Below are key valuation metrics over time for QGEN.

Stock Date P/S P/B P/E EV/EBIT
QGEN 2021-08-31 5.8 4.3 26.6 21.7
QGEN 2021-08-30 5.8 4.3 26.7 21.7
QGEN 2021-08-27 5.8 4.3 26.4 21.6
QGEN 2021-08-26 5.7 4.2 26.1 21.3
QGEN 2021-08-25 5.7 4.2 25.8 21.1
QGEN 2021-08-24 5.6 4.2 25.8 21.1

QGEN Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at 1540.26%.
  • The 5 year price growth rate now stands at 95.37%.
  • Its 3 year price growth rate is now at 56.88%.
Over the past 30 months, QGEN's revenue has gone up $687,663,000.

The table below shows QGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2,189.511 592.237 479.869
2021-03-31 2,065.455 570.52 448.582
2020-12-31 1,870.346 457.806 359.188
2020-12-31 1,870.346 457.806 359.188
2020-09-30 1,712.584 297.524 191.435
2020-09-30 1,712.584 297.524 191.435

QGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QGEN has a Quality Grade of B, ranking ahead of 78.67% of graded US stocks.
  • QGEN's asset turnover comes in at 0.375 -- ranking 126th of 681 Pharmaceutical Products stocks.
  • ALNY, RARE, and TXMD are the stocks whose asset turnover ratios are most correlated with QGEN.

The table below shows QGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.375 0.655 0.192
2021-03-31 0.363 0.658 0.199
2020-12-31 0.338 0.659 0.176
2020-12-31 0.338 0.659 0.176
2020-09-30 0.319 0.665 0.122
2020-09-30 0.319 0.665 0.122

QGEN Stock Price Chart Interactive Chart >

Price chart for QGEN

QGEN Price/Volume Stats

Current price $54.25 52-week high $59.00
Prev. close $53.99 52-week low $45.33
Day low $54.11 Volume 638,700
Day high $54.57 Avg. volume 763,113
50-day MA $53.45 Dividend yield N/A
200-day MA $51.04 Market Cap 12.37B

Qiagen N.V. (QGEN) Company Bio

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

QGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

QGEN Latest Social Stream

Loading social stream, please wait...

View Full QGEN Social Stream

Latest QGEN News From Around the Web

Below are the latest news stories about Qiagen Nv that investors may wish to consider to help them evaluate QGEN as an investment opportunity.

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

MANCHESTER, England & HILDEN, Germany, October 22, 2021--QIAGEN strengthens UK footprint with move to new Manchester facilities

Yahoo | October 22, 2021

Molecular Diagnostics Market Future Outlook with Key Focus on Global 2021-2028 | Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V.

The Latest research study released by CMI Global Molecular Diagnostics Market with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities,

OpenPR | October 21, 2021

Biobanking Market with Attractiveness, Competitive Landscape and Top Key Players (BD, Merck, Thermo Fisher, QIAGEN, Hamilton, VWR, BioCision) | Forecasts to 2027

Overview of the Global Biobanking Market: According to the world class Biobanking Market report, the leading players are focusing more on offering products at rational prices to gain a competitive advantage over the other players in the Healthcare industry. The main objective

OpenPR | October 21, 2021

QIAGEN (NYSE:QGEN) Stock Rating Lowered by Zacks Investment Research

QIAGEN (NYSE:QGEN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. They presently have a $56.00 target price on the stock. Zacks Investment Researchs price objective points to a potential upside of 4.56% from the companys previous close. According []

Dakota Financial News | October 21, 2021

Digital PCR Instrument Market 2021 Industry Emerging Trend, Top Players, Revenue Insights to 2027 |Bio-Rad Laboratories, QIAGEN, Roche, Thermo Fisher Scientific, Becton, Dickinson and Company

The Global Digital PCR Instrument Market from 2021 to 2027 study investigated by Market Intelligence Data examines the market in depth, emphasising data on many areas such as drivers, constraints, opportunities, threats, and worldwide markets, covering development trends, competitive landscape

OpenPR | October 20, 2021

Read More 'QGEN' Stories Here

QGEN Price Returns

1-mo 0.22%
3-mo 5.09%
6-mo 12.04%
1-year 10.13%
3-year 59.70%
5-year 110.31%
YTD 2.65%
2020 56.36%
2019 -1.89%
2018 11.38%
2017 6.30%
2016 1.34%

Continue Researching QGEN

Here are a few links from around the web to help you further your research on Qiagen Nv's stock as an investment opportunity:

Qiagen Nv (QGEN) Stock Price | Nasdaq
Qiagen Nv (QGEN) Stock Quote, History and News - Yahoo Finance
Qiagen Nv (QGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7749 seconds.